Antileishmanial high-throughput drug screening reveals drug candidates with new scaffolds.
Drugs currently available for leishmaniasis treatment often show parasite resistance, highly toxic side effects and prohibitive costs commonly incompatible with patients from the tropical endemic countries. In this sense, there is an urgent need for new drugs as a treatment solution for this neglect...
Main Authors: | Jair L Siqueira-Neto, Ok-Ryul Song, Hyunrim Oh, Jeong-Hun Sohn, Gyongseon Yang, Jiyoun Nam, Jiyeon Jang, Jonathan Cechetto, Chang Bok Lee, Seunghyun Moon, Auguste Genovesio, Eric Chatelain, Thierry Christophe, Lucio H Freitas-Junior |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2010-01-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | http://europepmc.org/articles/PMC2864270?pdf=render |
Similar Items
-
An image-based algorithm for precise and accurate high throughput assessment of drug activity against the human parasite Trypanosoma cruzi.
by: Seunghyun Moon, et al.
Published: (2014-01-01) -
Antileishmanial and Antitrypanosomes Drugs for the Current Century
by: José María Alunda
Published: (2023-12-01) -
An Overview on Anticancer Drugs with Antileishmanial Activity
by: Masoud Keighobadi, et al.
Published: (2018-06-01) -
The Potential of 2-Substituted Quinolines as Antileishmanial Drug Candidates
by: Philippe M. Loiseau, et al.
Published: (2022-04-01) -
Antileishmanial Drug Discovery and Development: Time to Reset the Model?
by: Ana Isabel Olías-Molero, et al.
Published: (2021-12-01)